Novartis at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Novartis takes part in 8 sessions at ACT 2026 in San Antonio. Its program centres on first-in-human dose selection and on oligonucleotide drugs such as siRNAs. Concrete topics include scaling doses from animals to people for eye and inhaled products, the minipig as a model of drug transfer into breast milk, and excipient safety in newborns.

Organization

ACT 2026 Attendance

Novartis

Basel, Switzerland

novartis.com

Pharmaceutical companies

Swiss pharmaceutical company; its preclinical safety teams present on first-in-human dosing, oligonucleotides, minipig lactation studies and excipient safety.

Session

Sun Nov 15
8:00am–11:30am

First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)

Translational safety · with Boehringer Ingelheim

8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox
8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics
8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri
9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis
10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis
10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim

Talk

Sun Nov 15
9:10am–9:30am

Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)

Inter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)

Translational safety

Talk

Sun Nov 15
10:00am–10:25am

Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)

Crossing the Species Divide in Inhaled Dosing (CE1-5)

Inhalation toxicology · Translational safety

Poster

Mon Nov 16
5:00pm–6:30pm

Coadministration of Two GalNAc-Conjugated siRNAs in Rats Produces Nonadverse Effects Similar to the Findings of the Individual siRNAs in General Toxicology Studies (P405)

Nelson Exhibit Ballroom · Poster P405

Biologics and new modalities

Poster

Mon Nov 16
5:00pm–6:30pm

Comparison between the Intravenous (IV) and Subcutaneous (SC) Routes of Administration of Inclisiran on Pharmacodynamics (PD), Toxicokinetics (TK) and Safety in the Nonhuman Primate (P409)

Nelson Exhibit Ballroom · Poster P409

Biologics and new modalities · Bioanalysis and biomarkers

Poster

Mon Nov 16
5:00pm–6:30pm

Neonatal Excipient Safety: Risk Assessment Considerations for Ethyl Benzoate in a Vulnerable Patient Population (P427)

Nelson Exhibit Ballroom · Poster P427

Chemical risk assessment

Poster

Mon Nov 16
5:00pm–6:30pm

The Göttingen Minipig as a Preclinical Model of Drug Transfer during Lactation (P440)

Nelson Exhibit Ballroom · Poster P440

DART · Animal models

Talk

Wed Nov 18
2:05pm–2:30pm

Part of Hot Topics (S18)

Cross-Industry Survey of Nonclinical Development Strategies for Oligonucleotide Therapeutics: Species Selection, Dose Setting, and Translational Approaches (S18-2)

Biologics and new modalities · Animal models

Instantly find 20 buyers from Novartis

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction